ClinicalTrials.gg
CompletedNCT02884089Updated Jan 4, 2019Results posted

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

A Phase 1 interventional study of Abemaciclib and Metformin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will look at how a single dose of abemaciclib will impact the body's ability to get rid of two other drugs, metformin and iohexol. In addition, this study will evaluate the effect of a single dose of abemaciclib on kidney function by measuring blood and urine markers. Side effects will also be documented.

Each participant will complete four study periods. During each study period, participants will stay in the clinical research unit for nine days and eight nights.

The study will last approximately 10 weeks, not including screening. Screening is required within 28 days prior to the start of the study.

This study is for research purposes only and is not intended to treat any medical condition.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy surgically sterile or females and sterile males
  • Have a (BMI) between 18 and 32 kilograms per meter squared (kg/m²), inclusive at screening

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to abemaciclib, metformin, iodine, iohexol, related compounds, or any components of the formulation
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence and/or positive antibodies of (HIV), , or
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Placebo comparator
    Placebo + Metformin

    Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.

    Drug: Metformin · Drug: Placebo

  • Experimental
    Abemaciclib + Metformin

    Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.

    Drug: Abemaciclib · Drug: Metformin

  • Placebo comparator
    Placebo + Iohexol

    Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.

    Drug: Iohexol · Drug: Placebo

  • Experimental
    Abemaciclib + Iohexol

    Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.

    Drug: Abemaciclib · Drug: Iohexol

Interventions

  • Administered orally

    Also known as: LY2835219

  • Administered orally

  • Administered intravenously (IV)

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of Metformin was evaluated.

    Time frame: Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose

  2. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin was evaluated.

    Time frame: Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose

  3. Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin

    Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin was evaluated.

    Time frame: Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose

Secondary outcomes

  1. Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol

    Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol was evaluated.

    Time frame: Pre infusion, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6 hours post infusion

07

Results

Posted Aug 7, 2018

Participant flow

Participants were randomized to one of the four sequences and received either placebo or Abemaciclib along with Metformin or Iohexol. A washout period of at least 16 days following Abemaciclib administration \& at least 5 days following placebo administration occurred between each period.

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started111199
Received at least one dose of study drug111199
Completed9999
Not completed2200
Withdrew: Dosing error2200
Washout Period 1
Participant flow — Washout Period 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started9999
Completed9798
Not completed0201
Withdrew: Lost to follow-up0101
Withdrew: Withdrawal by subject0100
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started9798
Completed8798
Not completed1000
Withdrew: Adverse event1000
Washout Period 2
Participant flow — Washout Period 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started8798
Completed8798
Not completed0000
Period 3
Participant flow — Period 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started8798
Completed8788
Not completed0010
Withdrew: Withdrawal by subject0010
Washout Period 3
Participant flow — Washout Period 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started8788
Completed8777
Not completed0011
Withdrew: Withdrawal by subject0010
Withdrew: Lost to follow-up0001
Period 4
Participant flow — Period 4
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started8777
Completed7677
Not completed1100
Withdrew: Withdrawal by subject0100
Withdrew: Lost to follow-up1000
Follow-up Visit
Participant flow — Follow-up Visit
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started7677
Completed6676
Not completed1001
Withdrew: Withdrawal by subject1001

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of Metformin was evaluated.

Time frame:
Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose
Reported as:
Geometric mean · Nanogram*Hour per Milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin
Nanogram*Hour per Milliliter (ng*h/mL)Placebo + 1000 mg Metformin400 mg Abemaciclib + 1000 mg Metformin
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin12100 ± 2316800 ± 30
PrimaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin was evaluated.

Time frame:
Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin
ng/mLPlacebo + 1000 mg Metformin400 mg Abemaciclib + 1000 mg Metformin
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin1550 ± 231940 ± 31
PrimaryPharmacokinetics (PK): Renal Clearance (CLr) of Metformin

Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin was evaluated.

Time frame:
Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose
Reported as:
Geometric mean · Liters per Hour (L/h)
Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin
Liters per Hour (L/h)Placebo + 1000 mg Metformin400 mg Abemaciclib + 1000 mg Metformin
Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin21.5 ± 2211.9 ± 35
SecondaryPharmacokinetics (PK): Renal Clearance (CLr) of Iohexol

Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol was evaluated.

Time frame:
Pre infusion, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6 hours post infusion
Reported as:
Geometric mean · Milliliter per minute (mL/min)
Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol
Milliliter per minute (mL/min)Placebo + 5 mL Iohexol400 mg Abemaciclib + 5 mL Iohexol
Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol89 ± 1785.6 ± 14

Adverse events

Collected over Up to 92 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + 1000 mg Metformin—0/33 (0%)8/33 (24.2%)
400 mg Abemaciclib + 1000 mg Metformin—0/35 (0%)11/35 (31.4%)
Placebo + 5 mL Iohexol—0/32 (0%)0/32 (0%)
400 mg Abemaciclib + 5 mL Iohexol—0/33 (0%)6/33 (18.2%)
Most frequent other events
Most frequent other events
EventPlacebo + 1000 mg Metformin400 mg Abemaciclib + 1000 mg MetforminPlacebo + 5 mL Iohexol400 mg Abemaciclib + 5 mL Iohexol
DiarrhoeaGastrointestinal disorders7/337/350/323/33
NauseaGastrointestinal disorders2/334/350/324/33
Abdominal PainGastrointestinal disorders1/334/350/320/33
VomitingGastrointestinal disorders0/334/350/323/33
FlatulenceGastrointestinal disorders2/331/350/320/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Study
Mean50.4 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female36
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino8
Not Hispanic or Latino32
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American18
White19
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
United States40
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilogram per square meter (kg/m^2))Overall Study
Mean27.25 ± 3.06
08

Study locations

1 site
  • Dallas Clinical Research Unit
    Dallas, Texas 75247, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2016
First posted
Aug 30, 2016
Start
Aug 2016
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results first posted
Aug 7, 2018
Last update
Jan 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02884089
Responsible party
Sponsor
First posted
Aug 30, 2016
Start date
Aug 2016
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Aug 7, 2018
Last update
Jan 4, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Metformin · Iohexol

Start the discussion